NKGen Biotech, Inc. Common Stock (NKGN)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	329.00 k	329.00 k	329.00 k	329.00 k	329.00 k	329.00 k
Cash burn (monthly)	(no burn)	95.25 k	2.49 mm	6.82 mm	2.00 mm	1.79 mm
Cash used (since last report)	n/a	692.96 k	18.08 mm	49.63 mm	14.55 mm	13.06 mm
Cash remaining	n/a	-363.96 k	-17.75 mm	-49.30 mm	-14.22 mm	-12.73 mm
Runway (months of cash)	n/a	-3.8	-7.1	-7.2	-7.1	-7.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

NKGN institutional ownership history Ownership history

32.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	33	4	+725.0%
Opened positions	29	3	+866.7%
Closed positions	0	5	EXIT
Increased positions	1	0	NEW
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	264.63 mm	71.18 mm	+271.8%
Total shares	14.50 mm	12.34 mm	+17.5%
Total puts	0.00	0.00
Total calls	30.70 k	0.00	NEW
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
NKMAX	12.15 mm	$44.60 mm	0.0%
Rivernorth Capital Management	652.43 k	$65.24 mm	NEW
Adage Capital Partners GP, L.L.C.	161.32 k	$14.04 mm	NEW
BNP Paribas Arbitrage	150.00 k	$14.81 mm	0.0%
Exos Asset Management	146.25 k	$13.33 mm	NEW
Balyasny Asset Management	139.89 k	$13.85 mm	NEW
Shaolin Capital Management	128.27 k	$11.16 mm	NEW
Jane Street	100.17 k	$8.71 mm	NEW
Healthcare Of Ontario Pension Plan Trust Fund	100.00 k	$9.90 mm	NEW
Kim	92.04 k	$9.11 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Rivernorth Capital Management	652.43 k	+652.43 k	NEW
Adage Capital Partners GP, L.L.C.	161.32 k	+161.32 k	NEW
Exos Asset Management	146.25 k	+146.25 k	NEW
Balyasny Asset Management	139.89 k	+139.89 k	NEW
Shaolin Capital Management	128.27 k	+128.27 k	NEW
Jane Street	100.17 k	+100.17 k	NEW
Healthcare Of Ontario Pension Plan Trust Fund	100.00 k	+100.00 k	NEW
Kim	92.04 k	+92.04 k	NEW
Taconic Capital Advisors	69.94 k	+69.94 k	NEW
Polar Asset Management Partners	60.00 k	+60.00 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

NKGN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
20 Dec 24	Graf Acquisition Partners IV	Common Stock	Other	Dispose J	No	No	0	63,634	0.00	2,082,507
20 Dec 24	Graf Acquisition Partners IV	Working Capital Warrants Common Stock	Sale back to company	Dispose D	No	No	11.5	93,334	1.07 mm	96,472
20 Dec 24	Graf Acquisition Partners IV	Private Placement Warrants Common Stock	Sale back to company	Dispose D	No	No	11.5	757,942	8.72 mm	1,145,831
6 Dec 24	Kathleen D. Scott	Stock Option Common Stock	Grant	Acquire A	No	No	0.438	500,000	219.00 k	500,000
6 Dec 24	Kathleen D. Scott	Stock Option Common Stock	Grant	Acquire A	No	No	1.62	300,000	486.00 k	300,000
6 Dec 24	Michael Klowden	Stock Option Common Stock	Grant	Acquire A	No	No	0.438	500,000	219.00 k	500,000
6 Dec 24	Michael Klowden	Stock Option Common Stock	Grant	Acquire A	No	No	1.62	300,000	486.00 k	300,000
6 Dec 24	Paul Y. Song	Stock Option Common Stock	Grant	Acquire A	No	No	0.438	2,000,000	876.00 k	2,000,000
6 Dec 24	Graf James A	Stock Option Common Stock	Grant	Acquire A	No	No	0.438	500,000	219.00 k	500,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

NKGen Biotech Selected As Stalking Horse Bidder For NKMax; NKGen Proposal Included Up To $18M In Committed Funding.

2 Dec 24

Upon closing, the transaction would secure global IP rights for NKGen.NKGen and its partners can begin to commercialize troculeucel in Korea, Japan and other markets where natural-killer ("NK") cell therapy is already

NKGen Biotech Receives Notifications From Nasdaq Related To Delayed Quarterly Report And Decision Of The Nasdaq Hearings Panel; The Company Does Not Intend To Appeal The Decision Letter At This Time And Intends To Deliver An Updated Plan Of Compliance To The Panel No Later Than January 7, 2025.

26 Nov 24

NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), today announced it received a notice (the "Notice") on November 20, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq")

12 Health Care Stocks Moving In Monday's Pre-Market Session

25 Nov 24

Press releases

From Benzinga Pro

NKGen Biotech Selected as Stalking Horse Bidder for NKMax

2 Dec 24

NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel

26 Nov 24

SANTA ANA, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), today announced it received a notice (the "Notice") on November 20, 2024 from the Listing